



HAL
open science

Activity, delivery and diversity of Type VI secretion effectors

Dukas Jurėnas, Laure Journet

► **To cite this version:**

Dukas Jurėnas, Laure Journet. Activity, delivery and diversity of Type VI secretion effectors. *Molecular Microbiology*, 2021, 115 (3), pp.383-394. 10.1111/mmi.14648 . hal-03022028

HAL Id: hal-03022028

<https://hal.science/hal-03022028>

Submitted on 24 Nov 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Activity, delivery and diversity of Type VI secretion effectors**

2
3 Dukas Jurėnas¹ & Laure Journet^{1*}

4
5 ¹ Laboratoire d'Ingėnierie des Systėmes Macromolėculaires, Institut de Microbiologie de la
6 Mėditerranėe, Aix-Marseille Universitė – CNRS, UMR 7255, 31 Chemin Joseph Aiguier, 13402
7 Marseille Cedex 20, France

8 *Corresponding author: Tel: +33 4 91 16 44 62; E-mail: ljournet@imm.cnrs.fr

9
10
11
12
13
14
15
16
17
18
19
20
21 *This is the peer reviewed version of the following article: Jurėnas D, Journet L. Activity,*
22 *delivery and diversity of Type VI secretion effectors. Mol Microbiol. 2020 Nov 20, which has*
23 *been published in final form at doi: 10.1111/mmi.14648. This article may be used for non-*
24 *commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived*
25 *Versions.*

45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70

SUMMARY

The bacterial type VI secretion system (T6SS) system is a contractile secretion apparatus that delivers proteins to neighbouring bacterial or eukaryotic cells. Antibacterial effectors are mostly toxins that inhibit growth of other species and help to dominate the niche. A broad variety of these toxins cause cell lysis of the prey cell by disrupting the cell envelope. Other effectors are delivered into the cytoplasm where they affect DNA integrity, cell division or exhaust energy resources. The modular nature of T6SS machinery allows different means of recruitment of toxic effectors to secreted inner tube and spike components that act as carriers. Toxic effectors can be translationally fused to the secreted components or interact with them through specialized structural domains. These interactions can also be assisted by dedicated chaperone proteins. Moreover, conserved sequence motifs in effector-associated domains are subject to genetic rearrangements and therefore engage in diversification of the arsenal of toxic effectors. This review discusses the diversity of T6SS secreted toxins and presents current knowledge about their loading on the T6SS machinery.

71 INTRODUCTION

72 The bacterial type VI secretion system (T6SS) is a protein secretion apparatus usually composed of
73 a membrane complex that anchors a cytoplasmic tail structurally and functionally similar to
74 contractile injection systems (Taylor *et al.*, 2018, Wang *et al.*, 2019) (Figure 1). In most T6SSs, the
75 membrane complex is composed of at least two inner membrane proteins and an outer membrane
76 lipoprotein assembled in the cell envelope (Rapisarda *et al.*, 2019). The pre-existing membrane
77 complex recruits an assembly platform called the baseplate (Brunet *et al.*, 2015, Nguyen *et al.*, 2017).
78 The baseplate is itself composed of six wedges arranged around a hub provided by the N-terminal
79 domain of the spike protein VgrG (Brunet *et al.*, 2015, Nazarov *et al.*, 2018). The wedges comprise
80 four proteins, including a phage-like receptor-binding protein that is responsible for baseplate
81 anchoring to the membrane complex (Zoued *et al.*, 2013, Cherrak *et al.*, 2018). Once docked to the
82 membrane complex, the baseplate initiates the assembly of a contractile tubular structure by the
83 polymerization of a tail tube surrounded by a contractile sheath (Leiman *et al.*, 2009, Basler *et al.*,
84 2012, Zoued *et al.*, 2016). The tail tube-sheath complex assembles in an extended conformation
85 (Basler *et al.*, 2012, Kudryashev *et al.*, 2015, Wang *et al.*, 2017). Its contraction leads to propulsion
86 of the tail tube across the envelope of the secreting bacterium and penetration into the target cells.
87 The inner tube is topped by the spike that is made of the trimeric VgrG protein and sharpened by a
88 conical PAAR protein. These constitute the needle that is secreted out of the bacterium and delivers
89 the effector proteins (Pukatzki *et al.*, 2007, Shneider *et al.*, 2013, Silverman *et al.*, 2013). The
90 effectors can be translationally fused to needle components, can be recruited to the needle via direct
91 interactions or with help of specific chaperone proteins also known as adaptors (Pukatzki *et al.*, 2007,
92 Shneider *et al.*, 2013, Bondage *et al.*, 2016, Unterweger *et al.*, 2017, Ma *et al.*, 2017a). The effector
93 proteins described to date exhibit a broad variety of different, mostly toxic, activities capable of
94 rapidly eliminating bacterial prey cells or altering the physiology of eukaryotic cells (Durand *et al.*,
95 2014, Russell *et al.*, 2014, Cianfanelli *et al.*, 2016b, Hachani *et al.*, 2016). To prevent elimination of

96 kin cells, the antibacterial T6SS toxin activity is counteracted by cognate immunity proteins acting
97 as anti-toxins. The acquisition and diversification of the effectors is associated with horizontal gene
98 transfer, gene duplications and recombination through conserved sequences that locate new toxins
99 and immunities at specific locations in the genome (Unterweger *et al.*, 2015, Salomon, 2016,
100 Koskiniemi *et al.*, 2014). The arsenal of effectors and the stockpile of immunities discussed in this
101 review is key for survival in the ecological niches with intense competition.

102

103 **ACTIVITY OF T6SS DELIVERED EFFECTORS**

104 In general, the activity of T6SS antibacterial effectors can be subdivided to lytic toxins that exert their
105 activity in the periplasm of the bacterial target and toxins active in their cytoplasm (Figure 2).
106 However, not all proteins delivered by T6SS are toxins, for example metal chelating proteins were
107 shown to be expelled through T6SS (Wang *et al.*, 2015, Si *et al.*, 2017a, Si *et al.*, 2017b, Han *et al.*,
108 2019). Similarly, effectors delivered into eukaryotic cells can alter the prey cells in more sophisticated
109 and subtle manners and therefore deserve a separate discussion (for reviews see (Hachani *et al.*, 2016,
110 Monjarás Feria & Valvano, 2020)). Some effectors target molecules that are conserved in both
111 bacterial and eukaryotic cells (e.g. phospholipids or DNA) and are therefore called trans-kingdom
112 effectors. The T6SS delivered repertoire is highly enriched in toxins inducing cell lysis (Zhang *et al.*,
113 2012, Smith *et al.*, 2020). Achieving rapid lysis of the prey cells can be beneficial in static
114 environments where prey cells can form colonies, as a layer of dead cells would otherwise form a
115 "corpse barrier" and limit access to the remaining prey cells (Borenstein *et al.*, 2015, Smith *et al.*,
116 2020). Moreover, lysis provides quick access to the released DNA of the prey and can therefore
117 stimulate horizontal gene transfer (Borgeaud *et al.*, 2015, Ringel *et al.*, 2017, Lin *et al.*, 2019).
118 Cytoplasmic acting toxins do not cause rapid cell lysis, nevertheless most of these toxins are very
119 efficient targeting highly conserved substrates, such as DNA or energy molecules like ATP or NAD⁺
120 (Alcoforado Diniz & Coulthurst, 2015, Whitney *et al.*, 2015, Ahmad *et al.*, 2019).

121 **Periplasmic acting effectors**

122 **Phospholipases.** Type VI lipase effectors (Tle) cause cell lysis of competing bacteria by
123 hydrolyzing phospholipids (Russell *et al.*, 2013, Jiang *et al.*, 2014, Ma *et al.*, 2014a, Jiang *et al.*, 2016,
124 Flaugnatti *et al.*, 2016). Tle toxins can be divided into five phylogenetically distinct families named
125 Tle1-Tle5 (Russell *et al.*, 2013). Tle1-4 members hydrolyze bonds between the glycerol and fatty
126 acid tails. They possess phospholipase A₁ activity – cleaving at first (sn1) glycerol position,
127 phospholipase A₂ activity – cleaving at second (sn2) position, or both (Russell *et al.*, 2013, Hu *et al.*,
128 2014, Jiang *et al.*, 2016, Flaugnatti *et al.*, 2016). These enzymes typically bear a GxSxG motif and a
129 putative S-H-D catalytic triad. All of the currently described Tle effectors comprise domains from
130 AB_hydrolase clan (CL0028), but can encode an additional membrane anchoring domain or domains
131 of unknown function (Hu *et al.*, 2014, Flaugnatti *et al.*, 2016, Jiang *et al.*, 2016, Berni *et al.*, 2019,
132 Wood *et al.*, 2019b). Tle5 members hydrolyze phospholipids between the phosphate and the head
133 group (at the sn3 position) and therefore possess phospholipase D activity. They are structurally
134 distinct from Tle1-4 and bear dual HxKxxxxD motifs (Russell *et al.*, 2013, Jiang *et al.*, 2014, Spencer
135 & Brown, 2015). Cleavage of phospholipid tails causes shrinking, inflating and eventual lysis of the
136 target cell (Ringel *et al.*, 2017). The Tle5 activity affects the phospholipid composition and can be
137 toxic due to accumulation of phosphatidic acid generated by cleavage of the head groups of
138 phospholipids (Russell *et al.*, 2013, Lery *et al.*, 2014). In addition to their antibacterial activities,
139 some Tle can target eukaryotic cells and act as transkingdom effectors. The *Pseudomonas aeruginosa*
140 PldB/Tle5b effector facilitates intracellular invasion of eukaryotic cells by activation of the PI3 kinase
141 pathway, while TplE/Tle4 activity leads to endoplasmic reticulum disruption, triggering autophagy
142 (Jiang *et al.*, 2016, Jiang *et al.*, 2014).

143 **Membrane disrupting / pore-forming toxins.** T6SS membrane disrupting effectors (Tme) or
144 pore-forming toxins exert their toxicity from the periplasm of the target cells, by inserting into the
145 inner membrane and causing membrane depolarization. Unlike other effectors, Tme effectors do not

146 possess catalytic activity and induce growth inhibition rather than cell lysis (Miyata *et al.*, 2013,
147 LaCourse *et al.*, 2018, Mariano *et al.*, 2019, Fridman *et al.*, 2020). These effectors share homologies
148 with pore-forming colicins or have predicted transmembrane helices (TMH) in their C-terminal
149 region (Miyata *et al.*, 2011, LaCourse *et al.*, 2018, Fridman *et al.*, 2020). These TMH can bear glycine
150 zipper motifs (LaCourse *et al.*, 2018), a motif commonly found in channel proteins or amyloid
151 proteins and known to promote homo-dimerization (Kim *et al.*, 2005, LaCourse *et al.*, 2018). *P.*
152 *aeruginosa* Tse4 and *Serratia marcescens* Ssp6 effectors form ion-selective pores, but are not
153 permeable to larger compounds (LaCourse *et al.*, 2018, Mariano *et al.*, 2019). In contrast, the
154 activities of VasX and *Vibrio parahaemolyticus* Tme1 and Tme2 induce permeability to larger
155 compounds such as propidium iodide or ONPG (Miyata *et al.*, 2013, Fridman *et al.*, 2020). However,
156 the precise molecular mechanisms underlying pore formation and/or membrane disruption induced
157 by these different toxins remain to be determined.

158 ***Peptidoglycan hydrolases.*** A broad spectrum of T6SS effectors cause cell lysis by degrading
159 peptidoglycan. They can be subdivided into those that hydrolyze the glycan backbone (glycoside
160 hydrolases, Tge family) and those that hydrolyze the peptide sidechains (amidases or peptidases, Tae
161 family). Tge effectors hydrolyze the N-acetylmuramic acid (NAM)- N-acetylglucosamine (NAG)
162 glycan strands (Hood *et al.*, 2010, Russell *et al.*, 2011, Whitney *et al.*, 2013, Ma *et al.*, 2018).
163 *Pseudomonas protegens* Tge2 presents a lysozyme-like fold and is neutralized by an immunity
164 protein similar to proteinaceous lysozyme inhibitors (Whitney *et al.*, 2013). In some cases, a
165 lysozyme-like effector is fused to VgrG, such as in *Vibrio cholerae* VgrG3 (Dong *et al.*, 2013b,
166 Brooks *et al.*, 2013). This is reminiscent of the VgrG homologue gp5 from phage T4 which also
167 carries a lysozyme domain to facilitate cell penetration. (Leiman *et al.*, 2009). The Tae (for Type VI
168 amidase effector) family of peptidoglycan hydrolases cleave the peptide stems or the peptidoglycan
169 cross-links. They bear different cleavage bond specificities: Tae1 and Tae4 are D,L-endopeptidases
170 whereas Tae2 and Tae3 are D,D-endopeptidases (Russell *et al.*, 2011, Russell *et al.*, 2012,

171 Srikannathasan *et al.*, 2013). In addition, amidase effectors specific to the NAM-L-Ala¹ bond have
172 been characterized (Ma *et al.*, 2018, Wang *et al.*, 2020). Recently, a novel *Salmonella enterica*
173 effector Tlde1 (Type 6 L-D-transpeptidase effectors) was characterized. It comprises a L-D
174 transpeptidase-like domain. However, Tlde1 does not crosslink NAM-NAG tetrapeptides, but retains
175 L,D-transpeptidase exchange activity (exchanging D-Ala⁴ by a non-canonical D-amino-acid) and
176 possesses an additional L,D-carboxypeptidase activity, cleaving tetrapeptides between mDAP³ and
177 D-Ala⁴. These modifications in peptide stems impair the biosynthesis of the peptidoglycan (Sibinelli-
178 Sousa *et al.*, 2020).

179 ***Metallopeptidases.*** Periplasmic-acting Type VI peptidase effectors (Tpe) belong to zinc
180 dependent metallopeptidases (Peptidase_MA, CL0126) that bear a HExxH zinc-binding motif (Zhang
181 *et al.*, 2012, Wood *et al.*, 2019a). *P. aeruginosa* Tpe1 is not active against peptidoglycan and was
182 rather suggested to cleave the lipoprotein anchors since it induced release of lipoproteins from the
183 membrane (Wood *et al.*, 2019a). A large variety of predicted T6SS peptidase effectors may present
184 diverse activities against periplasmic as well as cytoplasmic targets (Zhang *et al.*, 2012, Ma *et al.*,
185 2017b).

186

187 **Cytoplasmic acting effectors**

188 ***DNases.*** Most of the T6SS DNase effector (Tde) toxins belong to HNH superfamily, also
189 known as His-Me finger endonucleases (Zhang *et al.*, 2012, Koskiniemi *et al.*, 2013, Alcoforado
190 Diniz & Coulthurst, 2015, Pissaridou *et al.*, 2018, Pei *et al.*, 2020). A His-Me finger is a short 30-
191 amino acid motif formed by a β -hairpin followed by an α -helix ($\beta\beta\alpha$) that constitute a binding site for
192 a divalent metal ion (Jablonska *et al.*, 2017). The His-Me finger fits its α -helix into the DNA minor
193 groove aligning the β -hairpin with the catalytic histidine against the DNA backbone in a conformation
194 efficient for non-specific DNA hydrolysis. Although additional structural motifs can provide
195 specificity for nucleic acid structure or sequence (Jablonska *et al.*, 2017), no sequence specificity has

196 been demonstrated for any Tde proteins. Target cells exposed to DNase toxins form filaments due to
197 induction of the SOS response and eventually lose DAPI staining indicating complete degradation of
198 chromosomal DNA (Pissaridou *et al.*, 2018, Ma *et al.*, 2017a, Jana *et al.*, 2019). Apart from the HNH
199 family, other DNase domains have been identified in Tde effectors, such as those belonging to
200 families PoNe, Ntox and Tox-Rease (Ma *et al.*, 2014b, Bondage *et al.*, 2016, Bernal *et al.*, 2017,
201 Zhang *et al.*, 2012, Jana *et al.*, 2019). The HNH motif in the Tde effector from the uropathogenic
202 *Escherichia coli* is preceded by an additional Pyocin_S DNase domain (Ma *et al.*, 2017a, Nipic *et al.*,
203 2013). This effector is active against eukaryotes, where toxicity manifests in typical signs of DNA-
204 damage provoked apoptosis such as cell rounding and membrane blebbing (Nipic *et al.*, 2013).

205 **Deaminases.** Numerous families of deaminase toxins associated with the T6SS have been
206 predicted (Iyer *et al.*, 2011, Zhang *et al.*, 2012). Recently, an example of deaminase of the SCP1.201-
207 like family has been characterized (Mok *et al.*, 2020). *Burkholderia cenocepacia* DddA toxin
208 catalyzes deamination of cytosine to uracil in double-stranded DNA. The generated uracil is then a
209 substrate for base excision repair and results in C-G to T-A base pair transition (Mok *et al.*, 2020).
210 DddA toxin shows a preference for cytidine bases preceded by thymidine (5'-TC), and due to such
211 modest specificity it is extremely mutagenic (Mok *et al.*, 2020).

212 **NAD-glycohydrolases (NADases).** NAD(P) + glycohydrolase toxins (Tne, for Type 6
213 NADase Effector) degrade NAD(P) + to nicotinamide and ADP-ribose at the rate of ten to one
214 hundred thousand molecules per minute therefore quickly depleting the cellular pools of essential
215 NAD(P) + coenzymes primarily used for redox reactions (Whitney *et al.*, 2015, Tang *et al.*, 2018).
216 Drastically reduced NAD(P) + concentrations in the intoxicated cell lead to general growth inhibition
217 with cells maintaining structural integrity (Whitney *et al.*, 2015).

218 **(p)ppApp synthetases.** Tas1 effector secreted by a virulent clinical isolate of *P. aeruginosa*
219 structurally resembles RSH domain (RelA-SpoT homologue) enzymes that synthesize (p)ppGpp, a
220 signaling molecule that responds to nutritional stress (Ahmad *et al.*, 2019, Hauryliuk *et al.*, 2015).

221 Typical RSH enzymes phosphorylate GDP or GTP to yield ppGpp. Tas1 however is a pyrophosphate
222 kinase for adenosine nucleotides that phosphorylates ATP, ADP or AMP (Ahmad *et al.*, 2019). Due
223 to a high synthesis rate, reaching up to 180,000 phosphorylated ATP molecules per minute, attacked
224 cells are quickly depleted in ATP and ADP and accumulate (p)ppApp (Ahmad *et al.*, 2019). ATP and
225 ADP depletion have a pleiotropic impact on energy production as well as anabolic and catabolic
226 processes. In addition, (p)ppApp resembles (p)ppGpp and blocks purine synthesis by direct
227 interaction with PurF (Ahmad *et al.*, 2019). The accumulation of (p)ppApp could also contribute to
228 toxicity by binding a multitude of other (p)ppGpp targets (Ahmad *et al.*, 2019).

229 ***ADP-ribosyltransferase effectors.*** *Serratia proteamaculans* Tre1 is an antibacterial ADP-
230 ribosyltransferase, transferring the ADP-ribose moiety on protein targets upon hydrolysis of NAD +
231 (Ting *et al.*, 2018). Tre1 comprises a characteristic RSE-motif common to ADP-ribosyl transferases.
232 It exclusively ribosylates arginine residues and its main target is FtsZ – a bacterial tubulin-like protein
233 essential for cell division. Ribosylated FtsZ fails to polymerize, and hence cells are unable to septate,
234 form filaments and eventually lyse (Ting *et al.*, 2018). Another example of T6SS ADP-
235 ribosyltransferase effector is the *Aeromonas hydrophila* VgrG1 C-terminal domain that targets the
236 eukaryotic cytoskeleton (Suarez *et al.*, 2010). The C-terminal domain of VgrG1 ribosylates actin and
237 impedes its polymerization, leading to cell rounding, activation of caspases and eventually apoptosis
238 (Suarez *et al.*, 2010).

239

240 **Extracellular effectors**

241 As a metal scavenging strategy T6SS can secrete metallophore effectors directly into the extracellular
242 medium. This secretion strategy is contact-independent and allows metal acquisition. Proteins with
243 binding specificity for zinc, manganese and copper have been shown to be secreted by T6SS (Wang
244 *et al.*, 2015, Si *et al.*, 2017a, Si *et al.*, 2017b, Han *et al.*, 2019, DeShazer, 2019). *P. aeruginosa*
245 secreted TseF effector doesn't bind metals directly but binds the iron-loaded extracellular signaling

246 molecule PQS (*Pseudomonas* Quinolone System) (Lin *et al.*, 2017). Scavenged metals are then
247 imported back to the secreted bacterium by specific TonB-dependent transporters and provide a
248 growth advantage in scarce conditions in the host or in the environment or are used for specific
249 purposes such as oxidative stress resistance (Si *et al.*, 2017a, Si *et al.*, 2017b, Lin *et al.*, 2017).

250

251 **IMMUNITY PROTEINS**

252 To protect themselves from intoxication T6SS⁺ bacteria possess immunity genes adjacent to the
253 cognate toxin genes. As a rule, the immunity proteins protecting from periplasm-active toxins are
254 themselves located in the periplasm, being membrane anchored lipoproteins, periplasmic, or inner
255 membrane proteins (Russell *et al.*, 2013, Flaughnatti *et al.*, 2016, Fridman *et al.*, 2020, Wood *et al.*,
256 2019a). Effectors can also be encoded without adjacent immunity genes when they are active against
257 targets not found in the effector producing bacterium, for instance targets only found in eukaryotes
258 (Zhang *et al.*, 2012). Importantly, some bacteria can be intrinsically resistant to the anti-bacterial
259 toxins due to absence or difference of the target or due to specific responses (Hersch *et al.*, 2020,
260 Kamal *et al.*, 2020, Le *et al.*, 2020). Most immunity proteins are small single domain proteins that
261 typically engage in highly specific interactions with their cognate toxins and occlude their active sites
262 (Zhang *et al.*, 2012, Zhang *et al.*, 2013a, Zhang *et al.*, 2013b, Dong *et al.*, 2013a, Ding *et al.*, 2012,
263 Wang *et al.*, 2013, Whitney *et al.*, 2013, Robb *et al.*, 2016), or lock them in a dysfunctional
264 conformation (Lu *et al.*, 2014). However, some immunities have a dual function, as demonstrated for
265 Tri1, which binds the Tre1 toxin and also removes the ADP-ribosylation from toxin-modified proteins
266 via its ADP-ribosyl hydrolase domain (Ting *et al.*, 2018). As a result, Tri1 immunity was shown to
267 be rather promiscuous, able to neutralize various ADP-ribosylating toxins (Ting *et al.*, 2018).
268 Interestingly, multiple immunity genes can be organized into poly-immunity loci that are thought to
269 permit “cheating” in ecosystems charged with different bacterial species such as soil or microbiome
270 (Zhang *et al.*, 2012, Kirchberger *et al.*, 2017, Ross *et al.*, 2019, Barretto & Fowler, 2020). The

271 acquisition of new immunity genes is associated with horizontal gene transfer and recombination
272 (Zhang *et al.*, 2012, Kirchberger *et al.*, 2017).

273

274 **EFFECTOR LOADING AND DELIVERY**

275 T6SS effectors can be translationally fused to secreted T6SS core components - VgrG, PAAR or Hcp.
276 Otherwise, when encoded as separate genes, the effectors locate to VgrG, PAAR or Hcp through
277 specific interactions. These interactions can be assisted by dedicated chaperones or structural motifs
278 (Unterweger *et al.*, 2015, Unterweger *et al.*, 2017, Shneider *et al.*, 2013, Silverman *et al.*, 2013, Ma
279 *et al.*, 2017a) (Figure 3).

280 **Core components carrying effectors**

281 The VgrG spike protein forms trimers consisting of a cylinder shaped base followed by a β -helical
282 prism extension (gp5 needle-like domain) (Uchida *et al.*, 2014, Spinola-Amilibia *et al.*, 2016). The
283 gp5 needle domain can be followed by additional effector domains or effector-recruitment domains
284 (Pukatzki *et al.*, 2007, Flaugnatti *et al.*, 2016). PAAR domain proteins form cone shaped structures
285 (Shneider *et al.*, 2013, Rigard *et al.*, 2016). The base of the cone complements the C-terminal β -
286 strands of VgrG, however the termini of PAAR are surface exposed and therefore are apt for
287 extensions and are often C-terminally fused to various effector domains as well as recruitment
288 domains (Shneider *et al.*, 2013, Rigard *et al.*, 2016). Hcp proteins form hexameric rings that are
289 stacked to build a tube upon sheath formation. The central channel of an Hcp ring has a diameter of
290 roughly 40 Å which can accommodate small effector proteins (Mougous *et al.*, 2006, Silverman *et*
291 *al.*, 2013). Additionally, Hcp can also provide stability for its effectors and thus may contribute
292 chaperone functions (Silverman *et al.*, 2013).

293 Different effector groups may prefer certain types of core component carrier. For example,
294 phospholipase effectors are usually transported by VgrG (Russell *et al.*, 2013). Likely, due to their
295 relatively large size (60-100 kDa), they would not fit inside the lumen of the Hcp tube (Liang *et al.*,

296 2015, Unterweger *et al.*, 2015, Flaugnatti *et al.*, 2016, Wettstadt *et al.*, 2019, Ma *et al.*, 2020,
297 Flaugnatti *et al.*, 2020). Nevertheless, some Tle effectors fused to PAAR or Hcp were identified and
298 await characterization (Ma *et al.*, 2017a, Flaugnatti *et al.*, 2020). On the contrary, cytoplasmic acting
299 toxins are almost exclusively fused to PAAR, Hcp or specialized recruitment domains (Ma *et al.*,
300 2017a, Koskiniemi *et al.*, 2013, Pissaridou *et al.*, 2018, Bernal *et al.*, 2017, Jana *et al.*, 2019, Tang *et al.*,
301 *et al.*, 2018, Ting *et al.*, 2018, Ahmad *et al.*, 2019, Mok *et al.*, 2020). Structural motifs encoded in these
302 domains might facilitate translocation of these toxins to the cytoplasm of the prey.

303

304 **Adaptors/chaperones**

305 T6SS chaperones (also called adaptors) are accessory proteins that share several common features –
306 they are encoded adjacent to the toxin and are specific and indispensable for secretion of their cognate
307 effector, although not secreted themselves (Bondage *et al.*, 2016, Unterweger *et al.*, 2015, Cianfanelli
308 *et al.*, 2016a, Whitney *et al.*, 2015). While these proteins may facilitate proper folding of the effector,
309 their main function is to load their cognate toxin on the T6SS elements.

310 Eag (for Effector associated gene) family chaperones comprise a DcrB (previously DUF1795)
311 domain. They are required for complex formation between VgrG and their specific cognate N-
312 terminal PAAR-domain containing effectors (Whitney *et al.*, 2015, Cianfanelli *et al.*, 2016a, Quentin
313 *et al.*, 2018). Eag family chaperones are often encoded adjacent to evolved PAAR-toxins that bear
314 transmembrane domains and provide stability by direct interactions that cover the TM domains
315 (Quentin *et al.*, 2018). Specific Eag chaperones encoded in tandem with different toxins can recruit
316 them to the same VgrG spike and therefore facilitate diversification of effector load (Cianfanelli *et al.*,
317 2016a).

318 *Agrobacterium tumefaciens* Atu3641 is required for the secretion of the PAAR-fused Tde2 DNase. It
319 is so far the only example of DUF2169-containing chaperone family that seems to be associated with
320 the secretion of PAAR-fused effectors (Bondage *et al.*, 2016).

321 Tec/Tap family adaptors specifically interact with toxic effectors and with VgrG extensions or PAAR
322 extensions (Unterweger *et al.*, 2015, Liang *et al.*, 2015, Bondage *et al.*, 2016, Burkinshaw *et al.*,
323 2018). The *P. aeruginosa* TecT chaperone additionally requires a co-chaperone that is displaced upon
324 binding to PAAR protein extension (Burkinshaw *et al.*, 2018). Tec/Tap proteins share a structurally
325 uncharacterized DUF4123 domain (Unterweger *et al.*, 2015, Liang *et al.*, 2015). These chaperones
326 are encoded upstream their cognate effectors and have C-terminal ends specific to the N-terminal
327 domains of their cognate effectors (Unterweger *et al.*, 2015, Liang *et al.*, 2015). The central regions
328 of these chaperones are highly conserved and were proposed to be involved in recombination
329 generating diverse chimeras (Unterweger *et al.*, 2015).

330 Finally, *P. aeruginosa* DUF2875-containing Tla3 protein interacts with the Tle3 effector and with
331 the C-terminal extension of VgrG2b and was proposed to belong to a novel T6SS chaperone family
332 (Berni *et al.*, 2019).

333 **Recruitment domains and motifs**

334 While chaperones are usually stand-alone proteins, some domains decorating the VgrG-PAAR spike
335 perform a similar function, likely related to effector delivery. They range from smaller domains like
336 MIX (Marker for type sIX effectors) or FIX (Found in type sIX effectors) sequence motifs, TTR
337 (Transthyretin-like domains) or DUF2345 domains to larger structures like Rhs (Rearrangement hot
338 spot) core domains.

339 MIX and FIX are N-terminal sequences preceding the toxic domains in some T6SS effectors, but can
340 also be found embedded into VgrG or PAAR proteins (Salomon *et al.*, 2014, Jana *et al.*, 2019). MIX
341 are predicted to be primarily β stranded structures that consist of a highly hydrophobic central motif
342 and less conserved termini (Salomon *et al.*, 2014). MIX domains are of modular nature, can be
343 duplicated or associated to transposable elements, which suggests they serve for effector pool
344 diversification (Salomon, 2016, Salomon *et al.*, 2014). TTR domains exist as C-terminal VgrG or
345 PAAR extensions and were shown to bind effectors (Shneider *et al.*, 2013, Flaugnatti *et al.*, 2016,

346 Wood *et al.*, 2019b, Wettstadt *et al.*, 2019, Flaugnatti *et al.*, 2020). Bacterial TTR-like domains are
347 globular structures composed of two small β -sheets structurally resembling the eukaryotic TTR β -
348 sandwich structure (Flaugnatti *et al.*, 2020). In enteroaggregative *E. coli* VgrG^{EAEc}, the TTR is fused
349 to the VgrG gp5 needle-like domain through highly flexible loops (Flaugnatti *et al.*, 2020). TTR
350 interacts with the flexible N-terminal extension of Tle1 effector which inserts its β -sheets to form a
351 β -barrel with TTR (Flaugnatti *et al.*, 2020). In addition to recruitment function, TTRs can also provide
352 stability to the effectors as well as participate in effector neutralization (Wettstadt *et al.*, 2019,
353 Flaugnatti *et al.*, 2020). DUF2345 domain forms an extension of VgrG by continuing a β -prism
354 structure of the C-terminal gp5 domain of the VgrG spike (Flaugnatti *et al.*, 2020). DUF2345, as well
355 as long α -helices aligned against the length of the needle, make numerous contacts with loaded
356 effector. Together with the TTR domain, they can be considered an internal adaptor domain for direct
357 recruitment of the effectors (Flaugnatti *et al.*, 2020). DUF2345 domains can perform additional
358 functions. In *Acinetobacter baumannii*, the DUF2345 of VgrG is essential for T6SS assembly, while
359 the VgrG4 DUF2345 domain of *Klebsiella pneumoniae* is itself an antibacterial and antifungal toxic
360 effector inducing response to reactive oxygen species (Lopez *et al.*, 2020, Storey *et al.*, 2020). Rhs
361 are large proteins that were first identified as recombination-prone loci in chromosomes (Lin *et al.*,
362 1984). Certain classes of Rhs proteins are secreted through T6SS (Koskiniemi *et al.*, 2013,
363 Alcoforado Diniz & Coulthurst, 2015, Pei *et al.*, 2020). They are encoded downstream of VgrG or
364 T6SS chaperones (Eag or Tec/Tap) and comprise N-terminal PAAR or other VgrG interacting
365 (VIRN) domains (Cianfanelli *et al.*, 2016a, Pei *et al.*, 2020). The Rhs core region comprised of
366 spiralling β -sheets forms a shell-like structure that likely encloses the C-terminal toxin domain
367 (Jackson *et al.*, 2009, Zhang *et al.*, 2012, Alcoforado Diniz & Coulthurst, 2015, Jackson *et al.*, 2019).
368 It has been recently demonstrated that a T6SS secreted Rhs protein undergoes two autocleavages –
369 one at the N-terminus and one at the C-terminus (Pei *et al.*, 2020). These conserved autocleavages
370 were suggested to be a part of the toxin release mechanism (Pei *et al.*, 2020). Remarkably, Rhs-

371 associated toxins commonly act on targets within the cytoplasm, with the most common target
372 predicted to be nucleic acids (Zhang *et al.*, 2012). This in turn suggests that Rhs core could provide
373 a mechanism for the effectors to reach the cytoplasm. Rhs undergoes complex genetic rearrangements
374 to diversify the C-terminal sequences (Poole *et al.*, 2011). New Rhs toxins could be acquired by HGT
375 via recombination at conserved core regions (Jackson *et al.*, 2009, Koskiniemi *et al.*, 2014).

376

377 **CONCLUDING REMARKS AND FUTURE DIRECTIONS**

378 **Discovering the myriad of the effectors.** Bacteria can encode multiple T6SS loci and a plethora of
379 effectors. The disposition of different toxic effector-immunity pairs as well as cheating by collection
380 of the stand-alone immunities helps both hide and seek in the dense and diverse communities (Zhang
381 *et al.*, 2012, Kirchberger *et al.*, 2017, Ross *et al.*, 2019, Barretto & Fowler, 2020). Highly diverse
382 effector repertoire continues to be uncovered in different clinical and environmental isolates.
383 Comparative genomic strategies combined with genetic screening helps identifying novel T6SS
384 effectors and their targets (Fridman *et al.*, 2020). We are only beginning to learn about the acquisition
385 and integration of the novel effectors into the T6SS pathway. Bioinformatics studies suggest that
386 inherent conserved regions of the effector recruitment domains such as Rhs, DUF4123 or MIX have
387 diversifying capacity as they are prone to genetic rearrangements (Koskiniemi *et al.*, 2014,
388 Unterweger *et al.*, 2015, Salomon, 2016). However, only a few genetic studies have demonstrated the
389 engagement of distantly located so-called orphan-toxins (Koskiniemi *et al.*, 2014, Ma *et al.*, 2017a).
390 Other polymorphic toxic systems that were found to share some toxic domains with T6SS are
391 considered to be an alternative reservoir for novel toxic activities (Zhang *et al.*, 2012, Salomon, 2016).
392 The co-regulation of the T6SS expression with the DNA uptake could provide genetic material for
393 acquisition of novel effectors (Borgeaud *et al.*, 2015, Ringel *et al.*, 2017). Nevertheless, further
394 research is needed to gain full picture of the evolution of new effectors.

395 **Variations and limitations of T6SS based delivery.** In theory, some T6SS assemblies could
396 accommodate several different effectors at once, leading to the secretion of a cocktail of effectors in
397 one T6SS shot. Moreover, the same VgrG spike can accommodate different effectors using different
398 PAAR or adaptor proteins, and some effectors could be recruited to several different assemblies
399 (Whitney *et al.*, 2014, Cianfanelli *et al.*, 2016a, Burkinshaw *et al.*, 2018, Wood *et al.*, 2019b).
400 Processes that could coordinate the secretion of different effectors and the bases for the selection of
401 the effectors are so far unclear. First high-resolution Cryo-EM structures of T6SS secretion
402 spike/effector complexes revealed networks of highly specific interactions (Quentin *et al.*, 2018,
403 Flaugnatti *et al.*, 2020). These examples represent only a few out of many possible secretion complex
404 architectures. Moreover, to date we lack understanding of how spike/effector complex accommodates
405 in the baseplate and passes across the membrane complex. High resolution structures of different
406 architectures and different steps of assembly are needed to understand the molecular determinants of
407 this process. This information is crucial in order to design inhibitors that could block T6SS based
408 translocation of clinically important effectors. On the other hand, first attempts to use the T6SS for
409 delivery of heterologous proteins were successful but revealed some important limitations likely
410 related to steric hindrances (Ma *et al.*, 2009, Ho *et al.*, 2017, Wettstadt *et al.*, 2019, Wettstadt *et al.*,
411 2020). Therefore, better understanding of effector translocation at the molecular level could help
412 harness T6SS for therapeutic interests, such as injection of antibodies or antibiotics directly into the
413 target cells.

414

415 **ACKNOWLEDGEMENTS**

416 We thank Eric Cascales and the Cascales laboratory members for helpful discussions and support.
417 Our work on T6SS effectors is supported by the Centre National de la Recherche Scientifique
418 (CNRS), the Aix-Marseille Université (AMU), and a grant from the Agence Nationale de la

419 Recherche (ANR-18-CE15-0013-01) to L.J. D.J. is supported by a post-doctoral fellowship from the
420 Fondation pour la Recherche Médicale (SPF201809007142).

421

422 **CONFLICT OF INTEREST**

423 The authors have no conflict of interest to declare.

424

425 **REFERENCES**

426

- 427 Ahmad, S., Wang, B., Walker, M.D., Tran, H.R., Stogios, P.J., Savchenko, A., Grant, R.A., McArthur, A.G.,
428 Laub, M.T., and Whitney, J.C. (2019) An interbacterial toxin inhibits target cell growth by
429 synthesizing (p)ppApp. *Nature* **575**: 674-678.
- 430 Alcoforado Diniz, J., and Coulthurst, S.J. (2015) Intraspecies Competition in *Serratia marcescens* Is Mediated
431 by Type VI-Secreted Rhs Effectors and a Conserved Effector-Associated Accessory Protein. *J*
432 *Bacteriol* **197**: 2350-2360.
- 433 Barretto, L.A.F., and Fowler, C.C. (2020) Identification of A Putative T6SS Immunity Islet in *Salmonella* Typhi.
434 *Pathogens* **9**.
- 435 Basler, M., Pilhofer, M., Henderson, G.P., Jensen, G.J., and Mekalanos, J.J. (2012) Type VI secretion requires
436 a dynamic contractile phage tail-like structure. *Nature* **483**: 182-186.
- 437 Bernal, P., Allsopp, L.P., Filloux, A., and Llamas, M.A. (2017) The *Pseudomonas putida* T6SS is a plant
438 warden against phytopathogens. *ISME J* **11**: 972-987.
- 439 Berni, B., Soscia, C., Djermoun, S., Ize, B., and Bleves, S. (2019) A Type VI Secretion System Trans-Kingdom
440 Effector Is Required for the Delivery of a Novel Antibacterial Toxin in *Pseudomonas aeruginosa*.
441 *Front Microbiol* **10**: 1218.
- 442 Bondage, D.D., Lin, J.S., Ma, L.S., Kuo, C.H., and Lai, E.M. (2016) VgrG C terminus confers the type VI
443 effector transport specificity and is required for binding with PAAR and adaptor-effector complex.
444 *Proc Natl Acad Sci U S A* **113**: E3931-3940.
- 445 Borenstein, D.B., Ringel, P., Basler, M., and Wingreen, N.S. (2015) Established Microbial Colonies Can
446 Survive Type VI Secretion Assault. *PLoS Comput Biol* **11**: e1004520.
- 447 Borgeaud, S., Metzger, L.C., Scignari, T., and Blokesch, M. (2015) The type VI secretion system of *Vibrio*
448 *cholerae* fosters horizontal gene transfer. *Science* **347**: 63-67.
- 449 Brooks, T.M., Unterweger, D., Bachmann, V., Kostiuk, B., and Pukatzki, S. (2013) Lytic activity of the *Vibrio*
450 *cholerae* type VI secretion toxin VgrG-3 is inhibited by the antitoxin TsaB. *J Biol Chem* **288**: 7618-
451 7625.
- 452 Brunet, Y.R., Zoued, A., Boyer, F., Douzi, B., and Cascales, E. (2015) The Type VI Secretion TssEFGK-VgrG
453 Phage-Like Baseplate Is Recruited to the TssJLM Membrane Complex via Multiple Contacts and
454 Serves As Assembly Platform for Tail Tube/Sheath Polymerization. *PLoS Genet* **11**: e1005545.
- 455 Burkinshaw, B.J., Liang, X., Wong, M., Le, A.N.H., Lam, L., and Dong, T.G. (2018) A type VI secretion system
456 effector delivery mechanism dependent on PAAR and a chaperone-co-chaperone complex. *Nat*
457 *Microbiol* **3**: 632-640.
- 458 Cherrak, Y., Rapisarda, C., Pellarin, R., Bouvier, G., Bardiaux, B., Allain, F., Malosse, C., Rey, M., Chamot-
459 Rooke, J., Cascales, E., Fronzes, R., and Durand, E. (2018) Biogenesis and structure of a type VI
460 secretion baseplate. *Nat Microbiol* **3**: 1404-1416.
- 461 Cianfanelli, F.R., Alcoforado Diniz, J., Guo, M., De Cesare, V., Trost, M., and Coulthurst, S.J. (2016a) VgrG
462 and PAAR Proteins Define Distinct Versions of a Functional Type VI Secretion System. *PLoS Pathog*
463 **12**: e1005735.

- 464 Cianfanelli, F.R., Monlezun, L., and Coulthurst, S.J. (2016b) Aim, Load, Fire: The Type VI Secretion System, a
465 Bacterial Nanoweapon. *Trends Microbiol* **24**: 51-62.
- 466 DeShazer, D. (2019) A novel contact-independent T6SS that maintains redox homeostasis via Zn(2+) and
467 Mn(2+) acquisition is conserved in the Burkholderia pseudomallei complex. *Microbiol Res* **226**: 48-
468 54.
- 469 Ding, J., Wang, W., Feng, H., Zhang, Y., and Wang, D.C. (2012) Structural insights into the Pseudomonas
470 aeruginosa type VI virulence effector Tse1 bacteriolysis and self-protection mechanisms. *J Biol
471 Chem* **287**: 26911-26920.
- 472 Dong, C., Zhang, H., Gao, Z.Q., Wang, W.J., She, Z., Liu, G.F., Shen, Y.Q., Su, X.D., and Dong, Y.H. (2013a)
473 Structural insights into the inhibition of type VI effector Tae3 by its immunity protein Tai3. *Biochem
474 J* **454**: 59-68.
- 475 Dong, T.G., Ho, B.T., Yoder-Himes, D.R., and Mekalanos, J.J. (2013b) Identification of T6SS-dependent
476 effector and immunity proteins by Tn-seq in Vibrio cholerae. *Proc Natl Acad Sci U S A* **110**: 2623-
477 2628.
- 478 Durand, E., Cambillau, C., Cascales, E., and Journet, L. (2014) VgrG, Tae, Tle, and beyond: the versatile
479 arsenal of Type VI secretion effectors. *Trends Microbiol* **22**: 498-507.
- 480 Flaugnatti, N., Le, T.T., Canaan, S., Aschtgen, M.S., Nguyen, V.S., Blangy, S., Kellenberger, C., Roussel, A.,
481 Cambillau, C., Cascales, E., and Journet, L. (2016) A phospholipase A1 antibacterial Type VI
482 secretion effector interacts directly with the C-terminal domain of the VgrG spike protein for
483 delivery. *Mol Microbiol* **99**: 1099-1118.
- 484 Flaugnatti, N., Rapisarda, C., Rey, M., Beauvois, S.G., Nguyen, V.A., Canaan, S., Durand, E., Chamot-Rooke,
485 J., Cascales, E., Fronzes, R., and Journet, L. (2020) Structural basis for loading and inhibition of a
486 bacterial T6SS phospholipase effector by the VgrG spike. *EMBO J* **39**: e104129.
- 487 Fridman, C.M., Keppel, K., Gerlic, M., Bosis, E., and Salomon, D. (2020) A comparative genomics
488 methodology reveals a widespread family of membrane-disrupting T6SS effectors. *Nat Commun* **11**:
489 1085.
- 490 Hachani, A., Wood, T.E., and Filloux, A. (2016) Type VI secretion and anti-host effectors. *Curr Opin Microbiol*
491 **29**: 81-93.
- 492 Han, Y., Wang, T., Chen, G., Pu, Q., Liu, Q., Zhang, Y., Xu, L., Wu, M., and Liang, H. (2019) A Pseudomonas
493 aeruginosa type VI secretion system regulated by CueR facilitates copper acquisition. *PLoS Pathog*
494 **15**: e1008198.
- 495 Haurlyuk, V., Atkinson, G.C., Murakami, K.S., Tenson, T., and Gerdes, K. (2015) Recent functional insights
496 into the role of (p)ppGpp in bacterial physiology. *Nat Rev Microbiol* **13**: 298-309.
- 497 Hersch, S.J., Watanabe, N., Stietz, M.S., Manera, K., Kamal, F., Burkinshaw, B., Lam, L., Pun, A., Li, M.,
498 Savchenko, A., and Dong, T.G. (2020) Envelope stress responses defend against type six secretion
499 system attacks independently of immunity proteins. *Nat Microbiol* **5**: 706-714.
- 500 Ho, B.T., Fu, Y., Dong, T.G., and Mekalanos, J.J. (2017) Vibrio cholerae type 6 secretion system effector
501 trafficking in target bacterial cells. *Proc Natl Acad Sci U S A* **114**: 9427-9432.
- 502 Hood, R.D., Singh, P., Hsu, F., Guvener, T., Carl, M.A., Trinidad, R.R., Silverman, J.M., Ohlson, B.B., Hicks,
503 K.G., Plemel, R.L., Li, M., Schwarz, S., Wang, W.Y., Merz, A.J., Goodlett, D.R., and Mougous, J.D.
504 (2010) A type VI secretion system of Pseudomonas aeruginosa targets a toxin to bacteria. *Cell Host
505 Microbe* **7**: 25-37.
- 506 Hu, H., Zhang, H., Gao, Z., Wang, D., Liu, G., Xu, J., Lan, K., and Dong, Y. (2014) Structure of the type VI
507 secretion phospholipase effector Tle1 provides insight into its hydrolysis and membrane targeting.
508 *Acta Crystallogr D Biol Crystallogr* **70**: 2175-2185.
- 509 Iyer, L.M., Zhang, D., Rogozin, I.B., and Aravind, L. (2011) Evolution of the deaminase fold and multiple
510 origins of eukaryotic editing and mutagenic nucleic acid deaminases from bacterial toxin systems.
511 *Nucleic Acids Res* **39**: 9473-9497.
- 512 Jablonska, J., Matelska, D., Steczkiewicz, K., and Ginalski, K. (2017) Systematic classification of the His-Me
513 finger superfamily. *Nucleic Acids Res* **45**: 11479-11494.
- 514 Jackson, A.P., Thomas, G.H., Parkhill, J., and Thomson, N.R. (2009) Evolutionary diversification of an ancient
515 gene family (rhs) through C-terminal displacement. *BMC Genomics* **10**: 584.

- 516 Jackson, V.A., Busby, J.N., Janssen, B.J.C., Lott, J.S., and Seiradake, E. (2019) Teneurin Structures Are
517 Composed of Ancient Bacterial Protein Domains. *Front Neurosci* **13**: 183.
- 518 Jana, B., Fridman, C.M., Bosis, E., and Salomon, D. (2019) A modular effector with a DNase domain and a
519 marker for T6SS substrates. *Nat Commun* **10**: 3595.
- 520 Jiang, F., Wang, X., Wang, B., Chen, L., Zhao, Z., Waterfield, N.R., Yang, G., and Jin, Q. (2016) The
521 *Pseudomonas aeruginosa* Type VI Secretion PGAP1-like Effector Induces Host Autophagy by
522 Activating Endoplasmic Reticulum Stress. *Cell Rep* **16**: 1502-1509.
- 523 Jiang, F., Waterfield, N.R., Yang, J., Yang, G., and Jin, Q. (2014) A *Pseudomonas aeruginosa* type VI secretion
524 phospholipase D effector targets both prokaryotic and eukaryotic cells. *Cell Host Microbe* **15**: 600-
525 610.
- 526 Kamal, F., Liang, X., Manera, K., Pei, T.T., Kim, H., Lam, L.G., Pun, A., Hersch, S.J., and Dong, T.G. (2020)
527 Differential Cellular Response to Translocated Toxic Effectors and Physical Penetration by the Type
528 VI Secretion System. *Cell Rep* **31**: 107766.
- 529 Kim, S., Jeon, T.J., Oberai, A., Yang, D., Schmidt, J.J., and Bowie, J.U. (2005) Transmembrane glycine zippers:
530 physiological and pathological roles in membrane proteins. *Proc Natl Acad Sci U S A* **102**: 14278-
531 14283.
- 532 Kirchberger, P.C., Unterweger, D., Provenzano, D., Pukatzki, S., and Boucher, Y. (2017) Sequential
533 displacement of Type VI Secretion System effector genes leads to evolution of diverse immunity
534 gene arrays in *Vibrio cholerae*. *Sci Rep* **7**: 45133.
- 535 Koskiniemi, S., Garza-Sanchez, F., Sandegren, L., Webb, J.S., Braaten, B.A., Poole, S.J., Andersson, D.I.,
536 Hayes, C.S., and Low, D.A. (2014) Selection of orphan Rhs toxin expression in evolved *Salmonella*
537 *enterica* serovar Typhimurium. *PLoS Genet* **10**: e1004255.
- 538 Koskiniemi, S., Lamoureux, J.G., Nikolakakis, K.C., t'Kint de Roodenbeke, C., Kaplan, M.D., Low, D.A., and
539 Hayes, C.S. (2013) Rhs proteins from diverse bacteria mediate intercellular competition. *Proc Natl*
540 *Acad Sci U S A* **110**: 7032-7037.
- 541 Kudryashev, M., Wang, R.Y., Brackmann, M., Scherer, S., Maier, T., Baker, D., DiMaio, F., Stahlberg, H.,
542 Egelman, E.H., and Basler, M. (2015) Structure of the type VI secretion system contractile sheath.
543 *Cell* **160**: 952-962.
- 544 LaCourse, K.D., Peterson, S.B., Kulasekara, H.D., Radey, M.C., Kim, J., and Mougous, J.D. (2018) Conditional
545 toxicity and synergy drive diversity among antibacterial effectors. *Nat Microbiol* **3**: 440-446.
- 546 Le, N.H., Peters, K., Espallat, A., Sheldon, J.R., Gray, J., Di Venzio, G., Lopez, J., Djahanschiri, B., Mueller,
547 E.A., Hennon, S.W., Levin, P.A., Ebersberger, I., Skaar, E.P., Cava, F., Vollmer, W., and Feldman, M.F.
548 (2020) Peptidoglycan editing provides immunity to *Acinetobacter baumannii* during bacterial
549 warfare. *Sci Adv* **6**: eabb5614.
- 550 Leiman, P.G., Basler, M., Ramagopal, U.A., Bonanno, J.B., Sauder, J.M., Pukatzki, S., Burley, S.K., Almo, S.C.,
551 and Mekalanos, J.J. (2009) Type VI secretion apparatus and phage tail-associated protein
552 complexes share a common evolutionary origin. *Proc Natl Acad Sci U S A* **106**: 4154-4159.
- 553 Lery, L.M., Frangeul, L., Tomas, A., Passet, V., Almeida, A.S., Bialek-Davenet, S., Barbe, V., Bengoechea, J.A.,
554 Sansonetti, P., Brisse, S., and Tournebize, R. (2014) Comparative analysis of *Klebsiella pneumoniae*
555 genomes identifies a phospholipase D family protein as a novel virulence factor. *BMC Biol* **12**: 41.
- 556 Liang, X., Moore, R., Wilton, M., Wong, M.J., Lam, L., and Dong, T.G. (2015) Identification of divergent type
557 VI secretion effectors using a conserved chaperone domain. *Proc Natl Acad Sci U S A* **112**: 9106-
558 9111.
- 559 Lin, J., Zhang, W., Cheng, J., Yang, X., Zhu, K., Wang, Y., Wei, G., Qian, P.Y., Luo, Z.Q., and Shen, X. (2017) A
560 *Pseudomonas* T6SS effector recruits PQS-containing outer membrane vesicles for iron acquisition.
561 *Nat Commun* **8**: 14888.
- 562 Lin, L., Ringel, P.D., Vettiger, A., Durr, L., and Basler, M. (2019) DNA Uptake upon T6SS-Dependent Prey Cell
563 Lysis Induces SOS Response and Reduces Fitness of *Acinetobacter baylyi*. *Cell Rep* **29**: 1633-1644
564 e1634.
- 565 Lin, R.J., Capage, M., and Hill, C.W. (1984) A repetitive DNA sequence, rhs, responsible for duplications
566 within the *Escherichia coli* K-12 chromosome. *J Mol Biol* **177**: 1-18.

567 Lopez, J., Ly, P.M., and Feldman, M.F. (2020) The Tip of the VgrG Spike Is Essential to Functional Type VI
568 Secretion System Assembly in *Acinetobacter baumannii*. *mBio* **11**.

569 Lu, D., Zheng, Y., Liao, N., Wei, L., Xu, B., Liu, X., and Liu, J. (2014) The structural basis of the Tle4-Tli4
570 complex reveals the self-protection mechanism of H2-T6SS in *Pseudomonas aeruginosa*. *Acta*
571 *Crystallogr D Biol Crystallogr* **70**: 3233-3243.

572 Ma, A.T., McAuley, S., Pukatzki, S., and Mekalanos, J.J. (2009) Translocation of a *Vibrio cholerae* type VI
573 secretion effector requires bacterial endocytosis by host cells. *Cell Host Microbe* **5**: 234-243.

574 Ma, J., Bao, Y., Sun, M., Dong, W., Pan, Z., Zhang, W., Lu, C., and Yao, H. (2014a) Two functional type VI
575 secretion systems in avian pathogenic *Escherichia coli* are involved in different pathogenic
576 pathways. *Infect Immun* **82**: 3867-3879.

577 Ma, J., Pan, Z., Huang, J., Sun, M., Lu, C., and Yao, H. (2017a) The Hcp proteins fused with diverse extended-
578 toxin domains represent a novel pattern of antibacterial effectors in type VI secretion systems.
579 *Virulence* **8**: 1189-1202.

580 Ma, J., Sun, M., Dong, W., Pan, Z., Lu, C., and Yao, H. (2017b) PAAR-Rhs proteins harbor various C-terminal
581 toxins to diversify the antibacterial pathways of type VI secretion systems. *Environ Microbiol* **19**:
582 345-360.

583 Ma, J., Sun, M., Pan, Z., Lu, C., and Yao, H. (2018) Diverse toxic effectors are harbored by vgrG islands for
584 interbacterial antagonism in type VI secretion system. *Biochim Biophys Acta Gen Subj* **1862**: 1635-
585 1643.

586 Ma, L.S., Hachani, A., Lin, J.S., Filloux, A., and Lai, E.M. (2014b) *Agrobacterium tumefaciens* deploys a
587 superfamily of type VI secretion DNase effectors as weapons for interbacterial competition in
588 planta. *Cell Host Microbe* **16**: 94-104.

589 Ma, S., Dong, Y., Wang, N., Liu, J., Lu, C., and Liu, Y. (2020) Identification of a new effector-immunity pair of
590 *Aeromonas hydrophila* type VI secretion system. *Vet Res* **51**: 71.

591 Mariano, G., Trunk, K., Williams, D.J., Monlezun, L., Strahl, H., Pitt, S.J., and Coulthurst, S.J. (2019) A family
592 of Type VI secretion system effector proteins that form ion-selective pores. *Nat Commun* **10**: 5484.

593 Miyata, S.T., Kitaoka, M., Brooks, T.M., McAuley, S.B., and Pukatzki, S. (2011) *Vibrio cholerae* requires the
594 type VI secretion system virulence factor VasX to kill *Dictyostelium discoideum*. *Infect Immun* **79**:
595 2941-2949.

596 Miyata, S.T., Unterweger, D., Rudko, S.P., and Pukatzki, S. (2013) Dual expression profile of type VI
597 secretion system immunity genes protects pandemic *Vibrio cholerae*. *PLoS Pathog* **9**: e1003752.

598 Mok, B.Y., de Moraes, M.H., Zeng, J., Bosch, D.E., Kotrys, A.V., Raguram, A., Hsu, F., Radey, M.C., Peterson,
599 S.B., Mootha, V.K., Mougous, J.D., and Liu, D.R. (2020) A bacterial cytidine deaminase toxin enables
600 CRISPR-free mitochondrial base editing. *Nature* **583**: 631-637.

601 Monjarás Fera, J., and Valvano, M.A. (2020) An Overview of Anti-Eukaryotic T6SS Effectors. *Front Cell Infect*
602 *Microbiol* **10**: 584751.

603 Mougous, J.D., Cuff, M.E., Raunser, S., Shen, A., Zhou, M., Gifford, C.A., Goodman, A.L., Joachimiak, G.,
604 Ordonez, C.L., Lory, S., Walz, T., Joachimiak, A., and Mekalanos, J.J. (2006) A virulence locus of
605 *Pseudomonas aeruginosa* encodes a protein secretion apparatus. *Science* **312**: 1526-1530.

606 Nazarov, S., Schneider, J.P., Brackmann, M., Goldie, K.N., Stahlberg, H., and Basler, M. (2018) Cryo-EM
607 reconstruction of Type VI secretion system baseplate and sheath distal end. *EMBO J* **37**.

608 Nguyen, V.S., Logger, L., Spinelli, S., Legrand, P., Huyen Pham, T.T., Nhung Trinh, T.T., Cherrak, Y., Zoued, A.,
609 Desmyter, A., Durand, E., Roussel, A., Kellenberger, C., Cascales, E., and Cambillau, C. (2017) Type VI
610 secretion TssK baseplate protein exhibits structural similarity with phage receptor-binding proteins
611 and evolved to bind the membrane complex. *Nat Microbiol* **2**: 17103.

612 Nipic, D., Podlesek, Z., Budic, M., Crnigoj, M., and Zgur-Bertok, D. (2013) *Escherichia coli* uropathogenic-
613 specific protein, Usp, is a bacteriocin-like genotoxin. *J Infect Dis* **208**: 1545-1552.

614 Pei, T.T., Li, H., Liang, X., Wang, Z.H., Liu, G., Wu, L.L., Kim, H., Xie, Z., Yu, M., Lin, S., Xu, P., and Dong, T.G.
615 (2020) Intramolecular chaperone-mediated secretion of an Rhs effector toxin by a type VI secretion
616 system. *Nat Commun* **11**: 1865.

617 Pissaridou, P., Allsopp, L.P., Wettstadt, S., Howard, S.A., Mavridou, D.A.I., and Filloux, A. (2018) The
618 *Pseudomonas aeruginosa* T6SS-VgrG1b spike is topped by a PAAR protein eliciting DNA damage to
619 bacterial competitors. *Proc Natl Acad Sci U S A* **115**: 12519-12524.

620 Poole, S.J., Diner, E.J., Aoki, S.K., Braaten, B.A., t'Kint de Roodenbeke, C., Low, D.A., and Hayes, C.S. (2011)
621 Identification of functional toxin/immunity genes linked to contact-dependent growth inhibition
622 (CDI) and rearrangement hotspot (Rhs) systems. *PLoS Genet* **7**: e1002217.

623 Pukatzki, S., Ma, A.T., Revel, A.T., Sturtevant, D., and Mekalanos, J.J. (2007) Type VI secretion system
624 translocates a phage tail spike-like protein into target cells where it cross-links actin. *Proc Natl Acad Sci U S A* **104**: 15508-15513.

625
626 Quentin, D., Ahmad, S., Shanthamoorthy, P., Mougous, J.D., Whitney, J.C., and Raunser, S. (2018)
627 Mechanism of loading and translocation of type VI secretion system effector Tse6. *Nat Microbiol* **3**:
628 1142-1152.

629 Rapisarda, C., Cherrak, Y., Kooger, R., Schmidt, V., Pellarin, R., Logger, L., Cascales, E., Pilhofer, M., Durand,
630 E., and Fronzes, R. (2019) In situ and high-resolution cryo-EM structure of a bacterial type VI
631 secretion system membrane complex. *EMBO J* **38**.

632 Rigard, M., Broms, J.E., Mosnier, A., Hologne, M., Martin, A., Lindgren, L., Punginelli, C., Lays, C., Walker, O.,
633 Charbit, A., Telouk, P., Conlan, W., Terradot, L., Sjostedt, A., and Henry, T. (2016) *Francisella*
634 *tularensis* IgG Belongs to a Novel Family of PAAR-Like T6SS Proteins and Harbors a Unique N-
635 terminal Extension Required for Virulence. *PLoS Pathog* **12**: e1005821.

636 Ringel, P.D., Hu, D., and Basler, M. (2017) The Role of Type VI Secretion System Effectors in Target Cell Lysis
637 and Subsequent Horizontal Gene Transfer. *Cell Rep* **21**: 3927-3940.

638 Robb, C.S., Robb, M., Nano, F.E., and Boraston, A.B. (2016) The Structure of the Toxin and Type Six
639 Secretion System Substrate Tse2 in Complex with Its Immunity Protein. *Structure* **24**: 277-284.

640 Ross, B.D., Verster, A.J., Radey, M.C., Schmidtke, D.T., Pope, C.E., Hoffman, L.R., Hajjar, A.M., Peterson, S.B.,
641 Borenstein, E., and Mougous, J.D. (2019) Human gut bacteria contain acquired interbacterial
642 defence systems. *Nature* **575**: 224-228.

643 Russell, A.B., Hood, R.D., Bui, N.K., LeRoux, M., Vollmer, W., and Mougous, J.D. (2011) Type VI secretion
644 delivers bacteriolytic effectors to target cells. *Nature* **475**: 343-347.

645 Russell, A.B., LeRoux, M., Hathazi, K., Agnello, D.M., Ishikawa, T., Wiggins, P.A., Wai, S.N., and Mougous, J.D.
646 (2013) Diverse type VI secretion phospholipases are functionally plastic antibacterial effectors.
647 *Nature* **496**: 508-512.

648 Russell, A.B., Peterson, S.B., and Mougous, J.D. (2014) Type VI secretion system effectors: poisons with a
649 purpose. *Nat Rev Microbiol* **12**: 137-148.

650 Russell, A.B., Singh, P., Brittnacher, M., Bui, N.K., Hood, R.D., Carl, M.A., Agnello, D.M., Schwarz, S.,
651 Goodlett, D.R., Vollmer, W., and Mougous, J.D. (2012) A widespread bacterial type VI secretion
652 effector superfamily identified using a heuristic approach. *Cell Host Microbe* **11**: 538-549.

653 Salomon, D. (2016) MIX and match: mobile T6SS MIX-effectors enhance bacterial fitness. *Mob Genet*
654 *Elements* **6**: e1123796.

655 Salomon, D., Kinch, L.N., Trudgian, D.C., Guo, X., Klimko, J.A., Grishin, N.V., Mirzaei, H., and Orth, K. (2014)
656 Marker for type VI secretion system effectors. *Proc Natl Acad Sci U S A* **111**: 9271-9276.

657 Shneider, M.M., Buth, S.A., Ho, B.T., Basler, M., Mekalanos, J.J., and Leiman, P.G. (2013) PAAR-repeat
658 proteins sharpen and diversify the type VI secretion system spike. *Nature* **500**: 350-353.

659 Si, M., Wang, Y., Zhang, B., Zhao, C., Kang, Y., Bai, H., Wei, D., Zhu, L., Zhang, L., Dong, T.G., and Shen, X.
660 (2017a) The Type VI Secretion System Engages a Redox-Regulated Dual-Functional Heme
661 Transporter for Zinc Acquisition. *Cell Rep* **20**: 949-959.

662 Si, M., Zhao, C., Burkinshaw, B., Zhang, B., Wei, D., Wang, Y., Dong, T.G., and Shen, X. (2017b) Manganese
663 scavenging and oxidative stress response mediated by type VI secretion system in *Burkholderia*
664 *thailandensis*. *Proc Natl Acad Sci U S A* **114**: E2233-E2242.

665 Sibirinelli-Sousa, S., Hespanhol, J.T., Nicastro, G.G., Matsuyama, B.Y., Mesnage, S., Patel, A., de Souza, R.F.,
666 Guzzo, C.R., and Bayer-Santos, E. (2020) A Family of T6SS Antibacterial Effectors Related to I,d-
667 Transpeptidases Targets the Peptidoglycan. *Cell Rep* **31**: 107813.

668 Silverman, J.M., Agnello, D.M., Zheng, H., Andrews, B.T., Li, M., Catalano, C.E., Gonen, T., and Mougous, J.D.
669 (2013) Haemolysin coregulated protein is an exported receptor and chaperone of type VI secretion
670 substrates. *Mol Cell* **51**: 584-593.

671 Smith, W.P.J., Vettiger, A., Winter, J., Ryser, T., Comstock, L.E., Basler, M., and Foster, K.R. (2020) The
672 evolution of the type VI secretion system as a disintegration weapon. *PLoS Biol* **18**: e3000720.

673 Spencer, C., and Brown, H.A. (2015) Biochemical characterization of a *Pseudomonas aeruginosa*
674 phospholipase D. *Biochemistry* **54**: 1208-1218.

675 Spinola-Amilibia, M., Davo-Siguero, I., Ruiz, F.M., Santillana, E., Medrano, F.J., and Romero, A. (2016) The
676 structure of VgrG1 from *Pseudomonas aeruginosa*, the needle tip of the bacterial type VI secretion
677 system. *Acta Crystallogr D Struct Biol* **72**: 22-33.

678 Srikannathasan, V., English, G., Bui, N.K., Trunk, K., O'Rourke, P.E., Rao, V.A., Vollmer, W., Coulthurst, S.J.,
679 and Hunter, W.N. (2013) Structural basis for type VI secreted peptidoglycan DL-endopeptidase
680 function, specificity and neutralization in *Serratia marcescens*. *Acta Crystallogr D Biol Crystallogr*
681 **69**: 2468-2482.

682 Storey, D., McNally, A., Astrand, M., Sa-Pessoa Graca Santos, J., Rodriguez-Escudero, I., Elmore, B., Palacios,
683 L., Marshall, H., Hobley, L., Molina, M., Cid, V.J., Salminen, T.A., and Bengoechea, J.A. (2020)
684 *Klebsiella pneumoniae* type VI secretion system-mediated microbial competition is PhoPQ
685 controlled and reactive oxygen species dependent. *PLoS Pathog* **16**: e1007969.

686 Suarez, G., Sierra, J.C., Erova, T.E., Sha, J., Horneman, A.J., and Chopra, A.K. (2010) A type VI secretion
687 system effector protein, VgrG1, from *Aeromonas hydrophila* that induces host cell toxicity by ADP
688 ribosylation of actin. *J Bacteriol* **192**: 155-168.

689 Tang, J.Y., Bullen, N.P., Ahmad, S., and Whitney, J.C. (2018) Diverse NADase effector families mediate
690 interbacterial antagonism via the type VI secretion system. *J Biol Chem* **293**: 1504-1514.

691 Taylor, N.M.I., van Raaij, M.J., and Leiman, P.G. (2018) Contractile injection systems of bacteriophages and
692 related systems. *Mol Microbiol* **108**: 6-15.

693 Ting, S.Y., Bosch, D.E., Mangiameli, S.M., Radey, M.C., Huang, S., Park, Y.J., Kelly, K.A., Filip, S.K., Goo, Y.A.,
694 Eng, J.K., Allaire, M., Veessler, D., Wiggins, P.A., Peterson, S.B., and Mougous, J.D. (2018)
695 Bifunctional Immunity Proteins Protect Bacteria against FtsZ-Targeting ADP-Ribosylating Toxins. *Cell*
696 **175**: 1380-1392 e1314.

697 Uchida, K., Leiman, P.G., Arisaka, F., and Kanamaru, S. (2014) Structure and properties of the C-terminal
698 beta-helical domain of VgrG protein from *Escherichia coli* O157. *J Biochem* **155**: 173-182.

699 Unterweger, D., Kostiuk, B., Otjengerdes, R., Wilton, A., Diaz-Satizabal, L., and Pukatzki, S. (2015) Chimeric
700 adaptor proteins translocate diverse type VI secretion system effectors in *Vibrio cholerae*. *EMBO J*
701 **34**: 2198-2210.

702 Unterweger, D., Kostiuk, B., and Pukatzki, S. (2017) Adaptor Proteins of Type VI Secretion System Effectors.
703 *Trends Microbiol* **25**: 8-10.

704 Wang, J., Brackmann, M., Castano-Diez, D., Kudryashev, M., Goldie, K.N., Maier, T., Stahlberg, H., and
705 Basler, M. (2017) Cryo-EM structure of the extended type VI secretion system sheath-tube
706 complex. *Nat Microbiol* **2**: 1507-1512.

707 Wang, J., Brodmann, M., and Basler, M. (2019) Assembly and Subcellular Localization of Bacterial Type VI
708 Secretion Systems. *Annu Rev Microbiol* **73**: 621-638.

709 Wang, T., Ding, J., Zhang, Y., Wang, D.C., and Liu, W. (2013) Complex structure of type VI peptidoglycan
710 muramidase effector and a cognate immunity protein. *Acta Crystallogr D Biol Crystallogr* **69**: 1889-
711 1900.

712 Wang, T., Hu, Z., Du, X., Shi, Y., Dang, J., Lee, M., Heseck, D., Mobashery, S., Wu, M., and Liang, H. (2020) A
713 type VI secretion system delivers a cell wall amidase to target bacterial competitors. *Mol Microbiol*.

714 Wang, T., Si, M., Song, Y., Zhu, W., Gao, F., Wang, Y., Zhang, L., Zhang, W., Wei, G., Luo, Z.Q., and Shen, X.
715 (2015) Type VI Secretion System Transports Zn²⁺ to Combat Multiple Stresses and Host Immunity.
716 *PLoS Pathog* **11**: e1005020.

717 Wettstadt, S., Lai, E.M., and Filloux, A. (2020) Solving the Puzzle: Connecting a Heterologous *Agrobacterium*
718 *tumefaciens* T6SS Effector to a *Pseudomonas aeruginosa* Spike Complex. *Front Cell Infect Microbiol*
719 **10**: 291.

- 720 Wettstadt, S., Wood, T.E., Fecht, S., and Filloux, A. (2019) Delivery of the *Pseudomonas aeruginosa*
721 Phospholipase Effectors PldA and PldB in a VgrG- and H2-T6SS-Dependent Manner. *Front Microbiol*
722 **10**: 1718.
- 723 Whitney, J.C., Beck, C.M., Goo, Y.A., Russell, A.B., Harding, B.N., De Leon, J.A., Cunningham, D.A., Tran, B.Q.,
724 Low, D.A., Goodlett, D.R., Hayes, C.S., and Mougous, J.D. (2014) Genetically distinct pathways guide
725 effector export through the type VI secretion system. *Mol Microbiol* **92**: 529-542.
- 726 Whitney, J.C., Chou, S., Russell, A.B., Biboy, J., Gardiner, T.E., Ferrin, M.A., Brittnacher, M., Vollmer, W., and
727 Mougous, J.D. (2013) Identification, structure, and function of a novel type VI secretion
728 peptidoglycan glycoside hydrolase effector-immunity pair. *J Biol Chem* **288**: 26616-26624.
- 729 Whitney, J.C., Quentin, D., Sawai, S., LeRoux, M., Harding, B.N., Ledvina, H.E., Tran, B.Q., Robinson, H., Goo,
730 Y.A., Goodlett, D.R., Raunser, S., and Mougous, J.D. (2015) An interbacterial NAD(P)(+)
731 glycohydrolase toxin requires elongation factor Tu for delivery to target cells. *Cell* **163**: 607-619.
- 732 Wood, T.E., Howard, S.A., Forster, A., Nolan, L.M., Manoli, E., Bullen, N.P., Yau, H.C.L., Hachani, A.,
733 Hayward, R.D., Whitney, J.C., Vollmer, W., Freemont, P.S., and Filloux, A. (2019a) The *Pseudomonas*
734 *aeruginosa* T6SS Delivers a Periplasmic Toxin that Disrupts Bacterial Cell Morphology. *Cell Rep* **29**:
735 187-201 e187.
- 736 Wood, T.E., Howard, S.A., Wettstadt, S., and Filloux, A. (2019b) PAAR proteins act as the 'sorting hat' of the
737 type VI secretion system. *Microbiology* **165**: 1203-1218.
- 738 Zhang, D., de Souza, R.F., Anantharaman, V., Iyer, L.M., and Aravind, L. (2012) Polymorphic toxin systems:
739 Comprehensive characterization of trafficking modes, processing, mechanisms of action, immunity
740 and ecology using comparative genomics. *Biol Direct* **7**: 18.
- 741 Zhang, H., Gao, Z.Q., Wei, Y., Xu, J.H., and Dong, Y.H. (2013a) Insights into the cross-immunity mechanism
742 within effector families of bacteria type VI secretion system from the structure of StTae4-EcTai4
743 complex. *PLoS One* **8**: e73782.
- 744 Zhang, H., Zhang, H., Gao, Z.Q., Wang, W.J., Liu, G.F., Xu, J.H., Su, X.D., and Dong, Y.H. (2013b) Structure of
745 the type VI effector-immunity complex (Tae4-Tai4) provides novel insights into the inhibition
746 mechanism of the effector by its immunity protein. *J Biol Chem* **288**: 5928-5939.
- 747 Zoued, A., Durand, E., Bebeacua, C., Brunet, Y.R., Douzi, B., Cambillau, C., Cascales, E., and Journet, L. (2013)
748 TssK is a trimeric cytoplasmic protein interacting with components of both phage-like and
749 membrane anchoring complexes of the type VI secretion system. *J Biol Chem* **288**: 27031-27041.
- 750 Zoued, A., Durand, E., Brunet, Y.R., Spinelli, S., Douzi, B., Guzzo, M., Flaugnatti, N., Legrand, P., Journet, L.,
751 Fronzes, R., Mignot, T., Cambillau, C., and Cascales, E. (2016) Priming and polymerization of a
752 bacterial contractile tail structure. *Nature* **531**: 59-63.

753

754

755 **FIGURE LEGENDS**

756 **Figure 1. Schematic representation of the mechanism of action of Type VI secretion machinery.**

757 A membrane complex (1) recruits the baseplate (2) which allows the polymerization of the tail tube
758 surrounded by the sheath (3) until it reaches a complete elongated state (4). Upon contraction of the
759 sheath (5), the inner tube and the spike decorated with effectors are propelled into the target cell (6).
760 The membrane complex is shown in yellow, the baseplate in brown, the sheath in light blue. The

761 secreted components are shown in dark blue – the tail tube consists of a stack of hexameric Hcp rings
762 and spike consists of VgrG and PAAR. The effectors are shown in red.

763

764 **Figure 2. Anti-bacterial toxic activities of T6SS effectors.** The scheme shows the mode of action
765 of the different families of T6SS toxins. All toxins are shown in red.

766 **Tle** degrade membrane phospholipids (in light blue). **Tae and Tge** effectors degrade the
767 peptidoglycan (in golden) through amidase or glycoside hydrolase activities respectively. **Tme** form
768 pores in the inner membrane, leading to membrane depolarization (ions in black). One member of the
769 **Tpe** family was proposed to hydrolyze the lipid anchor of outer membrane lipoproteins (in green).
770 **Tas1** phosphorylates ATP and ADP (shown in yellow) leading to accumulation of (p)ppApp (shown
771 in orange). **Tne** degrade NAD(P) + (shown in pink) to nicotinamide (brown) and ADP-ribose (dark
772 purple), leading to the depletion of NAD(P) + cellular pools. **Tde** catalyze non-specific hydrolysis of
773 DNA (shown in black). **DddA** deaminates cytosine to uracil in the double stranded DNA. DddA
774 caused mutations are depicted in red, ammonia released as reaction product in grey. **Tre** ADP-
775 ribosylates protein target (here FtsZ) upon NAD + hydrolysis. FtsZ proteins are shown in blue, NAD
776 + in pink, ADP-ribose in dark purple.

777

778 **Figure 3: Currently described modes of effector loading on VgrG, Hcp or PAAR.** Effectors
779 (shown in red) can be fused to Hcp, VgrG or PAAR components or be encoded separately and interact
780 with these components directly or with the help of chaperones/adaptors. Chaperones can be either
781 encoded separately (shown in green) or constitute recruitment motifs that are integral parts of VgrG
782 or PAAR. Chaperones (Eag, Tep/Tec), Rhs domain, as well as a TTR domain are indicated.

783





Figure 1



Periplasmic effectors	Cytoplasmic effectors
Tle - Type 6 Lipase Effector	Tas - Type 6 Effector (p)ppApp Synthetase
Tae - Type 6 Amidase Effector	Tne - Type 6 NADase Effector
Tge - Type 6 Glycoside hydrolase Effector	Tde - Type 6 DNase Effector
Tme - Type 6 Membrane-disrupting Effector	DddA - DS-DNA Deaminase toxin A
Tpe - Type 6 Peptidase Effector	Tre - Type 6 ADP-Ribosyltransferase Effector

Figure 2




Figure 3